BSECompany Update12 Aug 2026 · 12 Aug 2026, 05:07 pm
We hereby submit intimation regarding approval for Two new products in Ethiopia.
Speciality Medicines Ltd · 544738
✦ AI Summary▲ PositiveOrder Win
Speciality Medicines Ltd has received regulatory approval from the competent health authority in Ethiopia for two additional speciality pharmaceutical formulations, Olanzapine Tablets 5 mg and Diazepam Tablets 5 mg, taking its total registered product portfolio in the Ethiopian market to 12 formulations.
Analysis Scores
Earnings Impact6/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Speciality Medicines Ltd - 544738 - Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 Regarding Approval For Two New Products In Ethiopia
Attachments (1)
📄pdf
Download →
2fb8f869-81a0-4526-9dd9-fb22ecf0e9cd.pdf
View document text
Exporter & Trader of
Speciality Medicines
Date: 12/08/2026
BSE Limited.
PJ Towers,
Dalal Street,
Mumbai – 400001
Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 regarding Approval for Two New Products in Ethiopia
Reference: Speciality Medicines Limited (Id: SPML; Code: 544738)
Dear Sir/Madam,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and
other applicable provisions, we wish to inform you that Speciality Medicines Limited, a speciality pharmaceutical
company with a diversified export presence across regulated and semi-regulated global markets, today
announced that it has received regulatory approval from the competent health authority in Ethiopia for two
additional speciality pharmaceutical formulations - Olanzapine Tablets 5 mg (Olazyn 5) and Diazepam Tablets 5
mg (Diazem 5).
With these approvals, the company’s total registered product portfolio in the Ethiopian market stands at 12
formulations, while its presence in Peru with 2 registered formulations, further strengthening its international
product portfolio and continued progress in regulatory registrations across key export markets.
A press release titled “Speciality Medicines Limited Secures Regulatory Approval for Two New Products in
Ethiopia” is also being submitted to the Stock Exchange in connection with the aforesaid Approval.
The above information is being submitted for the information of the Stock Exchange and the members of the
Company. Kindly take the above information on record.
Thanking you,
Yours Faithfully,
For, SPECIALITY MEDICINES LIMITED
(Formerly Known as Speciality Medicines Private Limited)
SUMIT GOYANI
Whole-Time Director
DIN: 07885780
Place: Mumbai
SPECIALITY MEDICINES LIMITED
(Formerly Known as Speciality Medicines Private Limited)
CIN: L85300GJ2021PLC120022
Corp. Office : Unit 27, Ground Floor, Andheri Sainath Premises Co Soc, 20 Mahakali Caves Road, Andheri (East), Mumbai, Maharashtra, India, 400093
Regd. Office : 913, One World West, S. No. 396, FP 119, Village- Vejalpur, Ahmedabad 380051, Gujarat, India
+91 99242 03751 / 99242 43751 info@specialitymedicine.com www.specialitymedicine.com